Interim findings from the ongoing AMBASSADOR trial revealed a significant DFS benefit with adjuvant pembrolizumab but no overall survival benefit at this point.
New research shows that ctDNA clearance following neoadjuvant treatment of muscle-invasive urothelial cancer can help predict response to therapy and the risk for relapse.